What Is BCMA

preview_player
Показать описание
IMF Chief Medical Officer Joseph Mikhael, MD, discusses BCMA (B-cell maturation antigen), a target for multiple myeloma treatment.

Please subscribe to our channel!

Find us online:

Category
Nonprofits & Activism
License
Standard YouTube License
  1. International Myeloma Foundation
  2. myeloma
  3. multiple myeloma
  4. cancer
  5. bone marrow cancer
  6. cancer treatment
Рекомендации по теме
What Is BCMA 0:03:19

What Is BCMA

What is BCMA? 0:05:12

What is BCMA? #myeloma

What is BCMA? 0:03:36

What is BCMA? #myeloma

What is BCMA 0:02:14

What is BCMA Directed therapy? #myeloma

The Role of 0:02:33

The Role of Anti-BCMA Therapies

BCMA: A new 0:03:10

BCMA: A new biomarker for multiple myeloma

BCMA-Targeted Therapies in 0:02:24

BCMA-Targeted Therapies in Multiple Myeloma

BCMA Therapies in 0:02:38

BCMA Therapies in Multiple Myeloma: 2023 Best of Hematology

How can BCMA 0:00:50

How can BCMA be used as a target for mutiple myeloma treatment?

Mechanisms behind the 0:01:48

Mechanisms behind the loss of BCMA in multiple myeloma & options for patients

Treating multiple myeloma 0:02:00

Treating multiple myeloma resistant to BCMA-targeted therapy

The Future of 0:01:23

The Future of BCMA-Targeting in Myeloma

CAR T-cells directed 0:01:07

CAR T-cells directed against BCMA in MM

Dr. Avigan on 0:01:16

Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

Future of BCMA-Targeted 0:04:37

Future of BCMA-Targeted Therapies in Multiple Myeloma

BCMA in Multiple 0:17:05

BCMA in Multiple Myeloma: Emerging Targeted Solutions

Using BCMA-targeting agents 0:01:38

Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma

Dr. Shah on 0:01:02

Dr. Shah on BCMA-Directed CAR T-Cell Therapy Research in R/R Multiple Myeloma

CAR T-cells: targeting 0:01:13

CAR T-cells: targeting BCMA

Dr. Berdeja Discusses 0:01:44

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

Dr. Stadtmauer on 0:01:06

Dr. Stadtmauer on BCMA-Targeting in Multiple Myeloma

BCMA Bispecific Toxicities, 0:03:41

BCMA Bispecific Toxicities, Access Considerations

BCMA: Predicting Outcomes 0:20:03

BCMA: Predicting Outcomes and Monitoring MM and CLL